ES2115643T3 - Esferoides a base de diltiazem y de un agente de esferonizacion. - Google Patents
Esferoides a base de diltiazem y de un agente de esferonizacion.Info
- Publication number
- ES2115643T3 ES2115643T3 ES92307333T ES92307333T ES2115643T3 ES 2115643 T3 ES2115643 T3 ES 2115643T3 ES 92307333 T ES92307333 T ES 92307333T ES 92307333 T ES92307333 T ES 92307333T ES 2115643 T3 ES2115643 T3 ES 2115643T3
- Authority
- ES
- Spain
- Prior art keywords
- controlled release
- diltiazem
- agent
- spheronization agent
- spheroids based
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Fertilizers (AREA)
Abstract
SE PRESENTA UN COMPUESTO DE LIBERACION CONTROLADA QUE COMPRENDE NUCLEOS ESFEROIDES QUE CONSTAN DE DITIAZEM O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y OPCIONALMENTE UN AGENTE ESFERONIZANTE, DICHOS NUCLEOS SE RECUBREN CON UNA CAPA DE LIBERACION CONTROLADA. EL AGENTE ESFERONIZANTE CUANDO ESTA PRESENTE ES PREFERIBLEMENTE CELULOSA MICROCRISTALINA. LA ETILCELULOSA ES EL AGENTE DE REVESTIMIENTO DE LIBERACION CONTROLADA MAS ADECUADO. EL RECUBRIMIENTO DE LIBERACION CONTROLADA CONTIENE PREFERIBLEMENTE UN PLASTIFICADOR, UN SURFACTANTE Y UN MODIFICADOR DE LA TEXTURA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919117361A GB9117361D0 (en) | 1991-08-12 | 1991-08-12 | Oral dosage form |
GB919122967A GB9122967D0 (en) | 1991-10-29 | 1991-10-29 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2115643T3 true ES2115643T3 (es) | 1998-07-01 |
Family
ID=26299395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92307333T Expired - Lifetime ES2115643T3 (es) | 1991-08-12 | 1992-08-11 | Esferoides a base de diltiazem y de un agente de esferonizacion. |
Country Status (14)
Country | Link |
---|---|
US (2) | US5670172A (es) |
EP (1) | EP0527637B1 (es) |
JP (1) | JP3019235B2 (es) |
KR (1) | KR100221695B1 (es) |
CN (1) | CN1052398C (es) |
AT (1) | ATE165513T1 (es) |
AU (1) | AU651715B2 (es) |
CA (1) | CA2075356A1 (es) |
DE (1) | DE69225278D1 (es) |
ES (1) | ES2115643T3 (es) |
FI (1) | FI923582A (es) |
IL (1) | IL102778A (es) |
NO (1) | NO304406B1 (es) |
PH (1) | PH31288A (es) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
FR2702160B1 (fr) * | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
SE9301220D0 (sv) * | 1993-04-14 | 1993-04-14 | Kabi Pharmacia Ab | Manufacturing matrices |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
US5834024A (en) * | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5914134A (en) * | 1997-01-27 | 1999-06-22 | Wockhardt Europe Limited | Process for the pulsatile delivery of diltiazem HCL and product produced thereby |
WO1999012526A1 (en) * | 1997-09-09 | 1999-03-18 | Alza Corporation | Pharmaceutical coating composition and method of use |
US7060734B1 (en) | 1997-09-09 | 2006-06-13 | Alza Corporation | Pharmaceutical coating composition and method of use |
US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
PL193273B1 (pl) | 1997-12-22 | 2007-01-31 | Euro Celtique Sa | Postać dawkowania doustnego |
PL341309A1 (en) * | 1997-12-22 | 2001-04-09 | Euro Celtique | Method of preventing overdosage of opioidic preparations |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
PT1178952E (pt) | 1999-05-14 | 2007-12-04 | Univ California | Novos moduladores da interleucina-1 e do factor alfa de necrose tumoral, síntese dos referidos moduladores e métodos de utilização dos referidos moduladores |
GB9913979D0 (en) | 1999-06-17 | 1999-08-18 | Univ Wales Medicine | Spheroid preparation |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR101476574B1 (ko) | 1999-10-29 | 2014-12-24 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
CN1423559A (zh) | 2000-02-08 | 2003-06-11 | 欧罗赛铁克股份有限公司 | 包含阿片样激动剂和拮抗剂的控释组合物 |
EP1259608B1 (en) | 2000-02-23 | 2009-08-12 | Life Technologies Corporation | Modified fluorescent proteins |
US6852031B1 (en) * | 2000-11-22 | 2005-02-08 | Igt | EZ pay smart card and tickets system |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
MXPA03003895A (es) | 2000-10-30 | 2003-07-28 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada. |
JP4395549B2 (ja) * | 2000-11-16 | 2010-01-13 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | 薬物及び発酵生成物の発見のための海洋放線菌分類群 |
IL155959A0 (en) | 2000-11-28 | 2003-12-23 | Fmc Corp | Edible pga (propylene glycol alginate) coating composition |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
US7943173B2 (en) | 2001-07-18 | 2011-05-17 | Purdue Pharma L.P. | Pharmaceutical combinations of oxycodone and naloxone |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
DE60232417D1 (de) | 2001-08-06 | 2009-07-02 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
CA2478523A1 (en) | 2002-04-05 | 2003-10-16 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
EP2422772A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
US7112581B2 (en) * | 2002-09-27 | 2006-09-26 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US20040208932A1 (en) * | 2003-04-17 | 2004-10-21 | Ramachandran Thembalath | Stabilized paroxetine hydrochloride formulation |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US20050049294A1 (en) * | 2003-06-20 | 2005-03-03 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US8217072B2 (en) * | 2003-06-20 | 2012-07-10 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
JP2007505315A (ja) * | 2003-09-12 | 2007-03-08 | インヴィトロジェン コーポレーション | 多重結合および活性アッセイ |
KR20060132698A (ko) * | 2004-01-23 | 2006-12-21 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 항균제로 유용한 비스-인돌 피롤 |
US7276530B2 (en) | 2004-04-30 | 2007-10-02 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1827385B1 (en) | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
CN103230394B (zh) * | 2004-12-03 | 2016-04-20 | 达纳-法伯癌症研究公司 | 治疗肿瘤性疾病的化合物及其用途 |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
CA2603031A1 (en) * | 2005-03-31 | 2006-10-05 | Rafael Armament Development Authority Ltd. | Apparatus for treating particles and liquids by ultrasound |
JP5666087B2 (ja) | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
WO2007015757A2 (en) | 2005-07-21 | 2007-02-08 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
HUE032156T2 (en) | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical preparations |
EP2068840A2 (en) * | 2006-07-21 | 2009-06-17 | LAB International SRL | Hydrophobic abuse deterrent delivery system |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
US20090017167A1 (en) * | 2007-07-11 | 2009-01-15 | Herbalife International Inc. | Mixture and beverage made therefrom for protecting cellular hydration |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
AU2008346870A1 (en) * | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
BRPI0821732A2 (pt) * | 2007-12-17 | 2015-06-16 | Labopharm Inc | Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada |
WO2009140287A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
SI2317991T1 (sl) * | 2008-07-07 | 2017-09-29 | Euro-Celtique S.A. | Uporaba opioidnih antagonistov za zdravljenje retencije urina |
ES2706407T3 (es) | 2009-03-10 | 2019-03-28 | Euro Celtique Sa | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona |
CA2782556C (en) | 2009-12-02 | 2018-03-27 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
ITFI20110172A1 (it) * | 2011-08-08 | 2013-02-09 | Valpharma Sa | Formulazione multiparticolata a rilascio modificato di diltiazem hcl. |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
AU2014295042B2 (en) | 2013-07-23 | 2017-03-30 | Mundipharma Pty Limited | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
CA2959965A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Pharmaceutical formulations comprising tetrahydrocurcumin and lipids |
CA2963923A1 (en) | 2014-10-08 | 2016-04-14 | Pacific Northwest Research Institute | Methods and compounds for increasing the potency of antifungal agents |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
EP3773612A4 (en) | 2018-03-28 | 2022-01-12 | Herbalife International of America, Inc. | ACETYLATION OF POLYSACCHARIDS |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456628A (en) * | 1981-01-07 | 1984-06-26 | Bauer Kurt H | Process for film-coating a particulate solid, and emulsions for conducting the process |
DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
US4643731A (en) * | 1985-08-16 | 1987-02-17 | Alza Corporation | Means for providing instant agent from agent dispensing system |
JPS62103012A (ja) * | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
IT1200217B (it) * | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
DE3709188A1 (de) * | 1987-03-20 | 1988-09-29 | Mannesmann Ag | Ausgiessrohr fuer metallurgische gefaesse |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
CA1323833C (en) * | 1987-04-28 | 1993-11-02 | Yatindra M. Joshi | Pharmaceutical compositions in the form of beadlets and method |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
BE1000794A4 (nl) * | 1987-07-30 | 1989-04-04 | Schelde Delta Bv Met Beperkte | Werkwijze voor het bij chemische processen immobiliseren van komponenten in een fluidumstroom, en inrichtingen die deze werkwijze toepassen. |
US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
US5219621A (en) * | 1987-10-16 | 1993-06-15 | Elan Corporation, Plc | Methods of treatment with diltiazem formulations |
ATE241987T1 (de) * | 1987-10-16 | 2003-06-15 | Elan Corp Plc | Diltiazem-zusammensetzungen mit kontrollierter wirkstoffabsorption |
IL88083A (en) * | 1987-11-06 | 1992-11-15 | Tanabe Seiyaku Co | Controlled release pharmaceutical dosage form and its preparation |
DE3739779A1 (de) * | 1987-11-24 | 1989-06-08 | Beiersdorf Ag | Pharmazeutische praeparate |
FR2623714B1 (fr) * | 1987-11-26 | 1990-04-20 | Ethypharm Sa | Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu |
FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
GB8805695D0 (en) * | 1988-03-10 | 1988-04-07 | Nycomed As | Enteric coated spheroidal granules |
FI101344B1 (fi) * | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
FR2630647B1 (fr) * | 1988-04-27 | 1991-08-16 | Sanofi Sa | Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant |
ZA899071B (en) * | 1988-11-30 | 1990-08-29 | Schering Corp | Sustained release diltiazem formulation |
SE506179C2 (sv) * | 1989-01-23 | 1997-11-17 | Ciba Geigy Ag | Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum |
SE8902699D0 (sv) * | 1989-08-09 | 1989-08-09 | Lejus Medical Ab | Diltiazem containing pharmaceutical compositios |
JPH0674206B2 (ja) * | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
ZA923474B (en) * | 1991-05-20 | 1993-01-27 | Marion Merrell Dow Inc | Diltiazem formulation |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
-
1992
- 1992-08-04 KR KR1019920013984A patent/KR100221695B1/ko not_active IP Right Cessation
- 1992-08-05 CA CA002075356A patent/CA2075356A1/en not_active Abandoned
- 1992-08-06 AU AU20880/92A patent/AU651715B2/en not_active Expired
- 1992-08-10 PH PH44791A patent/PH31288A/en unknown
- 1992-08-10 JP JP4234295A patent/JP3019235B2/ja not_active Expired - Lifetime
- 1992-08-10 IL IL10277892A patent/IL102778A/en not_active IP Right Cessation
- 1992-08-11 DE DE69225278T patent/DE69225278D1/de not_active Expired - Lifetime
- 1992-08-11 AT AT92307333T patent/ATE165513T1/de active
- 1992-08-11 NO NO923128A patent/NO304406B1/no not_active IP Right Cessation
- 1992-08-11 FI FI923582A patent/FI923582A/fi unknown
- 1992-08-11 EP EP92307333A patent/EP0527637B1/en not_active Expired - Lifetime
- 1992-08-11 ES ES92307333T patent/ES2115643T3/es not_active Expired - Lifetime
- 1992-08-12 CN CN92105698A patent/CN1052398C/zh not_active Expired - Lifetime
-
1995
- 1995-04-21 US US08/426,065 patent/US5670172A/en not_active Expired - Lifetime
-
1996
- 1996-06-18 US US08/666,636 patent/US5601845A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0527637A1 (en) | 1993-02-17 |
KR100221695B1 (ko) | 1999-09-15 |
KR930003906A (ko) | 1993-03-22 |
AU651715B2 (en) | 1994-07-28 |
DE69225278D1 (de) | 1998-06-04 |
US5601845A (en) | 1997-02-11 |
NO923128D0 (no) | 1992-08-11 |
IL102778A (en) | 1999-05-09 |
JP3019235B2 (ja) | 2000-03-13 |
AU2088092A (en) | 1993-02-18 |
CN1052398C (zh) | 2000-05-17 |
CN1069408A (zh) | 1993-03-03 |
NO923128L (no) | 1993-02-15 |
CA2075356A1 (en) | 1993-02-13 |
PH31288A (en) | 1998-07-06 |
JPH05201867A (ja) | 1993-08-10 |
EP0527637B1 (en) | 1998-04-29 |
FI923582A0 (fi) | 1992-08-11 |
ATE165513T1 (de) | 1998-05-15 |
NO304406B1 (no) | 1998-12-14 |
FI923582A (fi) | 1993-02-13 |
IL102778A0 (en) | 1993-01-31 |
US5670172A (en) | 1997-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2115643T3 (es) | Esferoides a base de diltiazem y de un agente de esferonizacion. | |
ES2084379T3 (es) | Particulas revestidas de pigmento, utiles en preparaciones cosmeticas, y procedimiento para su preparacion. | |
CA2124012A1 (fr) | Formulation de diltiazem a liberation prolongee | |
DE59507193D1 (de) | VERFAHREN ZU hERSTELLUNG EINER MANTELTABLETTE MIT SPITZEM KERN | |
FI891163A0 (fi) | Kontrollerat frigoerande farmaceutiskt preparat och foerfarande foer framstaellning av detta. | |
FI935298A0 (fi) | Anvaendning av rapamycin prolaekemedel som immunosuppressiva medel | |
KR920000313A (ko) | 제어성 약학 제제 | |
DK0591424T3 (da) | Diltiazem-holdigt lægemiddel med forlænget frigivelse | |
ATE239454T1 (de) | Orale morphinzubereitung in teilchenform | |
ATE92312T1 (de) | Pharmazeutische zubereitung mit verzoegerter freisetzung und seine herstellung. | |
KR930003905A (ko) | 약학적 결합 제제 | |
CA2044398A1 (en) | Programmed release oral solid pharmaceutical dosage form | |
NO894064L (no) | Hule, trykkoemfintlige akrylatpolymerkuler, samt fremgangsmaate for fremstilling av en vandig suspensjon som inneholder slike kuler. | |
DK1069891T3 (da) | Befugtelige mikrokapsler med ethylcelluseovertrukne kerner | |
HU9301499D0 (en) | Preparatives of controlled releasing of active agents | |
NO992098L (no) | Preparat med regulert avgivelse av aktiv forbindelse | |
SE8801591L (sv) | Straalmunstycke | |
NO921816L (no) | Vannbasert, tverrbindbart belegningspreparat, lagringsstabil forpakning av slikt preparat, samt anvendelse av preparatet | |
FI906382A (fi) | Pao polysilseskvioxan baserade magnetiserbara mikrobollar, foerfarande foer framstaellning av dessa och anvaendning av desamma i biologi. | |
DE3877621T2 (de) | Trockene orale theophyllinzubereitung mit verzoegerter freisetzung. | |
DK150982C (da) | Alfa-acyloxy-n,n'-diacylmalonamider til brug som aktivatorer for perforbindelser samt fremgangsmaade til fremstilling af saadanne forbindelser | |
NO893755D0 (no) | Anvendelse av kopolymerer inneholdende aminogrupper i vandig preparat som grunningsmiddel. | |
TH22631A (th) | ลูกกลมแบบใหม่สำหรับควบคุมการปล่อยสารและการเตรียมยาที่ประกอบด้วยลูกกลมชนิดเดียวกัน | |
NZ337208A (en) | sustained release pharmaceutical composition containing both slow release and fast release mini-granules coated with dexfenfluramine | |
DK0390135T3 (da) | Pyrroloquinolinderivater, deres anvendelse som antimikrobielle midler samt fremgangsmåde til fremstilling deraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 527637 Country of ref document: ES |